Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Bio-Path Holdings, Inc. BPTH OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
39/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Bio-Path Holdings, Inc. (BPTH) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 5 Buy.

BPTH Analyst Ratings

Buy
5
Ratings
5 Buy
Based on 5 analysts giving stock ratings to Bio-Path Holdings, Inc. in the past 3 months
Rating breakdown
Buy
5 100%
100%
Buy
5 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 CAPR
CAPR
Capricor Therapeutics, Inc.
$34.72
+0.52%
 ICVX
ICVX
Icosavax, Inc.
$15.31
-0.91%
 CBIO
CBIO
Catalyst Biosciences, Inc.
$19.52
+8.50%
 BNTC
BNTC
Benitec Biopharma Inc.
$13.25
+10.42%
 ACHV
ACHV
Achieve Life Sciences, Inc.
$3.61
+0.84%
 ALRN
ALRN
Aileron Therapeutics, Inc.
$2.11
+9.33%
 NXTC
NXTC
NextCure, Inc.
$12.77
+3.65%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message